• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Hematopoietic and mesenchymal stem cell transplantation for severe and refractory systemic lupus erythematosus
【24h】

Hematopoietic and mesenchymal stem cell transplantation for severe and refractory systemic lupus erythematosus

机译：造血和间充质干细胞移植治疗重度和难治性系统性红斑狼疮

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterized by multi-organ involvement leading to significant morbidity and mortality in predominantly young women. The underlying pathogenesis involves the emergence of autoreactive T and B lymphocytes, production of autoantibodies, formation and deposition of immune complexes in various tissues leading to inflammation and organ damage. Recently, growing evidence suggests that the functions of hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are disrupted in SLE pathology. And HSC or MSC transplantation (HSCT/MSCT) can offer an effective and safe therapy for the severe SLE patients, resulting in disease clinical remission and improvement of organ dysfunction. In this article, we provide a brief overview of current research of autologous or allogeneic HSCT/MSCT in SLE and describe our current understanding of the mechanisms by which it plays a part in treating SLE, for better understanding of the pathogenesis, diagnosis and treatment for SLE.
机译：系统性红斑狼疮（SLE）是一种自身免疫性疾病，其特征是多器官受累导致主要是年轻女性的大量发病和死亡。潜在的发病机制涉及自身反应性T和B淋巴细胞的出现，自身抗体的产生，免疫复合物在各种组织中的形成和沉积，从而导致炎症和器官损伤。最近，越来越多的证据表明，SLE病理破坏了造血干细胞（HSC）和间充质干细胞（MSC）的功能。 HSC或MSC移植（HSCT / MSCT）可以为重度SLE患者提供有效且安全的疗法，从而使疾病临床缓解并改善器官功能障碍。在本文中，我们简要概述了SLE中自体或异体HSCT / MSCT的最新研究，并描述了我们目前对其在SLE中发挥作用的机制的了解，以便更好地了解SLE的发病机理，诊断和治疗SLE。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号